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Probiotic microorganisms have been shown to provide specific health benefits 
when consumed as food supplements or as food components. The main 
problem of such products is the poor survival of the probiotic bacteria in the low 
pH of gastric fluid. However the use of synthetic excipients for enteric coating to 
prevent the exposure of microorganisms to gastric fluid is limited in food 
supplementary industry. Therefore the aim of this study was to develop an 
enteric coating formulation containing shellac as a natural polymer. Shellac 
possesses good resistance to gastric juice; the major disadvantage of this 
polymer is its low solubility in the intestinal fluid [1, 2]. Thus films containing 
different ratios of shellac and water-soluble polymers (sodium alginate, 
hydroxypropyl methylcellulose (HPMC) and polyvinylpyrrolidon (PVP)) or 
plasticizers (glycerol and glyceryl triacetate (GTA)) were prepared in order to 
analyse the films’ melting temperatures (Tm), the changes in enthalpy (ΔH), their 
capability of taking up water, and their solubility in different media. The release 
characteristics of the films were studied by loading pellets with Enterococcus 
faecium M74 and coating them with formulations containing different amounts of 
shellac and polymer or plasticized shellac. Using dissolution tests, performed 
according to USP XXXI paddle method, the resistance of the coatings to 
simulated gastric fluid (SGF, pH 1.2) and the release of cells in simulated 
intestinal fluid (SIF, pH 6.8) was investigated. 
The trials showed that an increasing amount of plasticizer results in a decrease 
of Tm and ΔH of the films whereat glycerol had a superior plasticization effect to 
GTA. The compatibility of films made of water-soluble polymers and shellac was 
also concentration dependent. HPMC and PVP showed superior compatibility 
with shellac compared to sodium alginate, since films containing shellac and 
more than 10% [w/w] sodium alginate tended to separate into two phases. In 
the end five formulations containing shellac and either 5% [w/w] glycerol, 10% 
[w/w] PVP, 20% [w/w] PVP, 10% [w/w] HPMC, or 5% [w/w] sodium alginate 
emerged as feasible for enteric coating purposes. 
[1]  Pearnchob N, Dashevsky A, Siepmann J, Bodmeier R. Shellac used as coating material for solid 
pharmaceutical dosage forms: understanding the effects of formulation and processing variables.  
S T P Pharma Sci. 2003; 13: 387–396. 
[2]  Limmatvapirat S, Limmatvapirat C, Puttipipatkhachorn S, Nuntanid J, Luangtana-anan M. Enhanced 
enteric properties and stability of shellac films through composite salts formation. Eur J Pharm 
Biopharm. 2007; 67: 690–698. doi:10.1016/j.ejpb.2007.04.008  556 Scientia  Pharmaceutica  www.scipharm.at 
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It was the purpose of this study to develop an oral oligonucleotide delivery 
system based on thiolated polymer/ reduced glutathione (GSH) system 
providing protective effect towards nucleases, permeation enhancement and 
controlled drug release. Polycarbophil-cysteine conjugate (PCP-Cys) was 
synthesized by the covalent attachment of cysteine to polycarbophil via amide 
bond formation. Incubation of 30-mer phosphorothioate oligonucleotide with 
DNase I and freshly collected intestinal fluid were performed in order to 
evaluate the protective effect of the polymer. Based on PCP-Cys conjugate 
together with GSH, permeation studies were performed on Caco-2 monolayer 
cell culture and on freshly excised intestinal rat mucosa in Ussing chambers. 
Additional drug release studies of tablets containing PCP–Cys, reduced GSH, 
and the oligonucleotide were performed in 100 mM phosphate buffer pH 6.8. 
PCP-Cys displayed 223±13.8 µmol thiol groups per gram polymer. After 4 h the 
unprotected ODNs, which were incubated with DNase I and intestinal fluid, were 
significantly degraded by 61 % and 80 %, respectively. In contrast, less than 41 
% (in DNase I) and 60 % (in intestinal fluid) of the ODNs were degraded in the 
presence of 0.02 % (m/v) of PCP-Cys. Permeation studies demonstrated due to 
the addition of PCP-Cys/GSH an 8-fold and 10-fold increase in the apparent 
permeability coefficient (Papp) on Caco-2 monolayer and on intestinal rat 
mucosa in comparison to the buffer only, respectively. Tablets containing PCP–
Cys, GSH, and oligonucleotide showed a sustained drug release over 2 h. 
According to these results the PCP-Cys/GSH system might be a promising tool 
for the oral administration of oligonucleotide. 
This work was supported by a scholarship from the Austrian Federal Ministry for 
Education, Science, and Culture to RM. www.scipharm.at Scientia  Pharmaceutica  557 
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Mupirocin-loaded microparticles (MP) were designed to control drug release at 
the skin surface assuring that drug remains localized at the application site and 
does not unnecessarily enter into the systemic circulation [1]. These reservoirs 
release active ingredient over an extended period of time maintaining effective 
drug concentration on the skin, at the same time reducing undesired side 
effects.  
The goal of this research was to design controlled release MP with acrylic 
polymer using spray-drying technique and assess influence of feed composition 
(in terms of native drug/polymer physical form and solvent used) and 
preselected drug loadings (1:5 and 2:1 (w/w) drug:polymer proportion) on MP 
performance under the same processing conditions. Physicochemical prop-
erties of MP were evaluated using thermal (MDSC, TGA), spectroscopic (FT-IR) 
and X-ray analyses and correlated with encapsulation efficacy and in vitro drug 
release achieved. Morphology and particle size were determined using low 
angle laser light scattering (LALLS) and scanning electron microscopy (SEM).  
Spray-drying of feed dispersion has formed partially coated crystalline MP with 
reduced encapsulation efficacy, irregular morphology and poor ability to control 
drug release irrespective of drug loading. Conversely, solid dispersions 
prepared from spray-drying feed solution have shown that drug/polymer 
miscibility, morphology and in vitro drug release were dependent on drug 
loading and solvent used [2]. The superior control of drug release from MP was 
achieved for the higher drug loading (2:1 (w/w) drug:polymer proportion) using 
solvents in the following order: methanol ≈ methanol+ethanol(50:50) > isopropyl 
alcohol+acetone (40:60). MP were amorphous, with smooth and spherical 
morphology. The higher polymer loading (1:5 (w/w) drug:polymer proportion) 
yielded less control over drug release regardless of solvents used, with MP 
exhibiting significantly different morphologies.  
Acrylic-based solid dispersions were confirmed as suitable microcarriers for 
controlled drug release using simple and scaleable spray-drying technique. 
[1]  Embil K, Nacht S. The Microsponge Delivery System (MDS): a topical delivery system with reduced 
irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 
1996; 13: 575–388. doi:10.3109/02652049609026042 
[2]  Wang FJ, Wang CH. Sustained release of etanidazole from spray dried microspheres prepared by 
non-halogenated solvents. J Control Release. 2002; 81: 263–280.  
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Monoglycerides, Phytantriol and a few other lipophilic molecules self-assemble 
in bulk in presence of water to form well defined liquid crystalline phases. Their 
structure can be tuned by temperature variation and/or by addition of oils. This 
leads to gel-like or fluid systems with a large internal interface between water 
and oil domains with different bulk viscosities. These nanostructured phases 
can be dispersed in the excess water phase by addition of an external stabilizer 
and energy input leading to internally self-assembled particles, so-called 
ISAsomes [1–4]. These ISAsomes are potential carrier systems for hydrophilic, 
amphiphilic and lipophilic functional molecules.  
The hierarchical structure can be extended to a next level by gellifying the 
continuous aqueous phase by the addition of polymers like κ–Carrageenan or 
Methylcellulose. This leads to a new type of hydrogel, loaded with ISAsomes 
[5, 6]. Differently to the original oil-continuous bulk phase, the viscosity of this, 
now water-continuous, system can be varied in a wide range by composition. 
These gels can even be dried into foils and re-dispersed on demand.  
Finally, we can use the oil-continuous nanostructured bulk phase to create 
concentrated, stable water in oil emulsions having a paste-like consistency and 
water content from 50% up to 90% by volume. No additional stabilizer is needed 
to create these systems. They have a great potential as delivery systems for 
functional molecules in very different fields like pharmaceutical and cosmetic 
applications, as well as in food science and agro-chemistry. 
[1]  de Campo L, Yaghmur A, Sagalowicz L, Watzke H, and Glatter O, Reversible Phase Transition in 
Emulsified Nano-Structured Lipid Systems. Langmuir. 2004; 20: 5254–5261. doi:10.1021/la0499416 
[2]  Yaghmur A, de Campo L, Salentinig S, Sagalowicz L, Leser M, Glatter O. Emulsified microemulsions 
and oil-containing liquid crystalline phases. Langmuir. 2005; 21: 569–577. doi:10.1021/la0482711 
[3]  Yaghmur A, de Campo L, Salentinig S, Sagalowicz L, Leser M, Glatter O. Oil-loaded monolinolein-
based particles with confined inverse discontinuous cubic structure (Fd3m). Langmuir. 2006; 22: 517–
521. doi:10.1021/la052109w 
[4]  Moitzi Ch, Guillot S, Fritz G, Salentinig S, Glatter O, Phase Reorganisation in Self-Assembled 
Systems Through Interparticle Material Transfer. Adv Mater. 2007; 19, 1352-1358. 
doi:10.1002/adma.200601679 
[5]  Guillot S, Tomšič M, Sagalowicz L, Leser M E, Glatter O, Internally Self-Assembled Particles 
Entrapped in Thermosensitive Hydrogels. J Colloid Interface Sci. 2009; 330, 175–179. 
doi:10.1016/j.jcis.2008.10.065 
[6] Tomšič M, Guillot S, Sagalowicz L, Leser M E, Glatter O, Internally Self-Assembled Thermoreversible 
Gelling Emulsions: ISAsomes in Methylcellulose, Kappa-Carrageenan, and Mixed Hydrogels. 
Langmuir. 2009; 25: 9525–9534. doi:10.1021/la900766c www.scipharm.at Scientia  Pharmaceutica  559 
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Background: Lactose intolerance is the inability to metabolize lactose because 
of the absence of the enzyme lactase. It is estimated that 75–90% of birth 
lactase levels are lost by most people after weaning. The prevalence of lactase 
deficiency ranges widely with the ethnic background from 2–15% among 
Northern Europeans to 95–100% among Asians [1]. Nowadays, lactose 
intolerance is usually controlled by strict adherence to a loactose-free or 
lactose-reduced diet. Moreover, as an alternative, capsules or tablets containing 
microbial-derived ß-galactosidase are available. However, this treatment is 
inconvenient for patients since these formulations have to be administered 
immediately before or together with lactose-containing diet because of their 
short-acting effect. 
Aim: Therefore, the present work is aimed to develop an innovative long-acting 
peroral formulation for the treatment of lactose intolerance. 
Methods: Biodegradable and biocompatibale polymeric microcarriers 
(2.78±1.05µm in diameter) were manufactured from poly(D,L-lactide-co-
glycolide) (PLGA) using spray-drying. They were functionalized with 
β-galactosidase from Kluyveromyces lactis and targeted with wheat germ 
agglutinin (WGA), which might prolong the residence time of particles in the 
small intestine. The particle-bound enzyme activity, the mucoadhesive as well 
as the cytoadhesive properties were assessed. 
Results: The highest particle-bound enzyme activity (1470 U ß-galactosidase 
per gram PLGA) was obtained with hexamethylene diamine as a spacer using 
carbodiimide method representing a 6-fold increase as compared to particles 
without spacer. Surface immobilisation of WGA enhanced considerably the 
particle binding to porcine mucin layer (mucoadhesion) and Caco-2 cell 
monolayers (cytoadhesion). 
Conclusions: PLGA-microparticles, surface-modified with active ß-galactosidase 
as enzyme substitute and WGA as a targeter, are able to bind to enterocytes 
and thereby to prolong the intestinal residence time. It is a promising approach 
towards a promising approach towards a more convenient therapy of lactose 
deficiency and intolerance. 
[1]  Harrington LK, Mayberry JF. A re-appraisal of lactose intolerance. Int J Clin Pract. 2008; 62: 1541–
1546. doi:10.1111/j.1742-1241.2008.01834.x 560 Scientia  Pharmaceutica  www.scipharm.at 
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Skin is main target for UV-oxidative stress and their antioxidant defenses can 
be quickly overcome. The consequences are reflected at the molecular and 
cellular level. Here, most important organelle included in survival pathway are 
mitochondria. Recently significant activation of mitochondria-mediated signaling 
cascades by resveratrol (RSV) has been discovered [1].  
RSV is a naturally occurring polyphenolic phytoalexin, which has many 
beneficial biological effects but on the other hand possess some limitations. 
Few of these are: poor water solubility, high metabolic rate and frequent dosage 
–dependent effect in the cellular environment [2]. One of recent progresses that 
can satisfy all these obstacles of RSV is design of nanosized drug delivery 
system [3].  
The protective effects of RSV in solution or loaded into SLN (SLN-RSV) on 
radiated keratinocytes were studied comparing with the effects on non-radiated 
cells.  
Cosequences of damaged effect of UV-radiation was slightly changed cell 
morphology, as some fragments of actin fibers appeared and mitochondria 
activity was weakened and they were dispersed over whole cytoplasm. 
However, only SLN with incorporated RSV at 100 μM preserved normal cell 
morphology and improved mitochondria activity, while the other samples (RSV 
at 10 or 100 μM and also SLN-RSV at 10 μM) showed any significant difference 
regarding radiated control cells. These effects are ascribed to the transfer of 
RSV by nanoparticles intracellularly – integrating among mitochondria, where 
RSV can best realize its “anti-stress” potential.  
To conclude, the results clearly revealed the hypothesis that loading of RSV into 
SLN significantly improve bioavailability and diminish UV-related damage of 
keratinocytes, and thus providing better photoprotection of cells compared to 
the application of RSV in solution.  
[1]  Kalra N, Roy P, Prasad S, Shukla Y. Resveratrol induces apoptosis involving mitochondrial pathways 
in mouse skin tumorigenesis. Life Sci. 2008; 82: 348–358. doi:10.1016/j.lfs.2007.11.006 
[2]  Kundu JK, Surh Y.-J. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic 
perspectives. Cancer Lett. 2008; 269: 243–261. doi:10.1016/j.canlet.2008.03.057 
[3]  Kristl J, Teskac K, Caddeo C, Abramovic Z, Sentjurc M. Improvements of cellular stress response on 
resveratrol in liposomes. Eur J Pharm Biopharm. 2009; 73: 253–259. doi:10.1016/j.ejpb.2009.06.006 www.scipharm.at Scientia  Pharmaceutica  561 
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Cationic SLN formulations were developed and optimized in terms of cationic 
lipid/surfactant ratio and production parameters. 5wt% of Compritol 888 ATO 
(COM, Gattefosse) or Imwitor 900(IMW,BASF) were used, 0.4–1.0wt% of cetyl-
trimethylammonium bromide (CTAB, Sigma) and 0.1–1.0 wt% of Lutrol F68 
(BASF) were tested. Formulations were produced in triplicate. SLN were 
prepared by modified microemulsion method [1], which was further optimized in 
terms of velocity and time of high shear homogenization step. Freeze-drying 
was performed on DuraDry MP at −45°C/184 mT during 6 days. Samples were 
freeze-dryed with 5.0% or 10.0% of Glucose (Sigma) or Sucrose (BDH 
Chemicals) or without cryoprotectants. Reconsitution was performed by re-
hydratation, vortexing during 3min and applying ultrasound during 30s. A 
Zetasizer NanoSeries (Malvern) was used to determine average hydrodynamic 
diameter (z-ave), polydispersity (PdI) and zeta potential (ZP) 
Optimized formulation consisted of 5.0% solid lipid, 0.5% CTAB and 0.25% 
Lutrol F68, yielding particles with z-ave=159nm, PdI=0.34 and ZP=54.8 mV 
(IMW) and z-ave=180nm, PdI=0.272 and ZP=56.2 mV (COM). These param-
eters remained unchanged during 8 days of storage at 8°C. Samples dried 
without cryoprotectants yielded light powdery product which could be 
redispersed easily; freeze-dried samples with saccharides tested yielded solid 
products. 
Cationic SLN formulations intended for gene delivery were designed and 
optimized. Particles with z-ave below 200nm and low PdI were produced. These 
SLN showed good stability of 15 days .Suitability of cationic SLN for freeze-
drying without cryoprotectants was confirmed [2].  
The authors whish to thank Dr. Fernando Nunes for cooperation in freeze-
drying experiments. This work was supported by grant SFRH/BD/60552/2009 
from FCT and by Nadacia Slovenskeho Plynarenskeho Priemyslu. 
[1]  Shah KA, Joshi MD, Patravale VB. Biocompatible Microemulsions for Fabrication of Glyceryl 
Monostearate Solid Lipid Nanoparticles (SLN) of Tretinoin. J Biomed Nanotechnol. 2009; 5: 396–400. 
doi:10.1166/jbn.2009.1048 
[2]  Vighi E, Ruozi B, Montanari M, Battini R, Leo E. Re-dispersible cationic solid lipid nanoparticles 
(SLNs) freeze-dried without cryoprotectors: Characterization and ability to bind the pEGFP-plasmid. 
Eur J Pharm Biopharm. 2007; 67: 320–328. doi:10.1016/j.ejpb.2007.02.006 562 Scientia  Pharmaceutica  www.scipharm.at 
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Pharmaceutical secondary manufacturing has long stood in stark contrast to the 
drug discovery end of the business, as well as to other sectors, when it comes 
to innovation such as continuous manufacturing. Is that about to change? The 
traditional business model is breaking down with consequent pressures on all 
parts of the pharma value chain. Manufacturing’s contribution to improving yield, 
reducing time, cost and waste is increasingly critical. Regulation which 
previously had insisted on batch testing is now moving to be much more 
supportive of real time product release and process analysis, heralding a future 
where the validation and establishment of continuous manufacturing will be 
easier. 
Integration of each process stage is crucial for continuous manufacturing. 
However, pharma companies tend to work with ‘islands of automation’ where 
every unit of operation is more or less an independent from an integration point 
of view. 
Another key barrier is that these changes require companies to work in a more 
multi-disciplinary way, crossing system worlds. For the first time, if you are in 
analytics you have to speak to people in process control and so on. Multi-
disciplinary teams are an absolute must but not everyone is ready for that. The 
relatively slow uptake of process analytical technology (PAT), crucial for 
continuous manufacturing, following the FDA’s 2004 PAT initiative, highlights 
the challenge facing companies. 
Mindset changes and internal culture changes will be key to the successful 
introduction of PAT as a first step towards continuous manufacturing. The 
companies that are first to overcome the barriers will not just reap the reward of 
increased competitiveness. Because of the stage of its introduction, they have 
the opportunity to implement the technology to a higher level than in industries 
where it is already established. From being a laggard, secondary manufacturing 
has the potential to become a trendsetter. 
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Granular flows are of paramount importance in industry and nature. To 
understand, e.g., the effect of various process parameters on the final product 
performance is critical. In industry, the flow in agitated mixing equipment 
basically consists of granular flow over a blade. While previous experimental 
and numerical work [1,  2] could reveal some features of this flow situation, 
information like single-blade mixing efficiency or the principal parameters that 
influence this flow are still scarce. 
We performed excessive high-speed video imaging of dry and wet granular flow 
under a controlled atmosphere in a 3D mixer as well as in a novel 2D flow 
setup. We use particle image velocimetry (PIV) to measure the velocity of the 
granular bed from the top (3D system) as well as in a cross section of the blade. 
Discrete-Element-Method (DEM) simulations are used to help interpreting our 
experimental results. The ultimate goal was to quantify the mixing in bladed 
mixers (e. g., high-shear granulators). 
We show results for the instantaneous, time-averaged as well as fluctuating 
velocity fields for the flow over a single blade. Our results indicate that the bed 
height in front of the blade has a significant effect on the flow pattern. Also, the 
flow situation changes when multiple blades are used and the blade-to-blade 
distance is changed. Finally, we quantify the mixing efficiency of a single-blade 
passage using image analysis. 
[1]  Remy B, Khinast JG, Glasser BJ. Discrete Element Simulation of Free Flowing Grains in a Four-
Bladed Mixer. AIChE J. 2009; 55: 2035–2048. doi:10.1002/aic.11876 
[2]  Radl S, Kalvoda E, Glasser BJ, Khinast JG. Mixing Characteristics of Wet Granular Matter in a Bladed 
Mixer. Powder Technol. 2010; 200: 171–189. doi:10.1016/j.powtec.2010.02.022 
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Porous particles are present in various technical applications as well as in the 
field of medical treatment. The latter involves amongst others the production of 
highly porous and respirable particles to serve as solid inhalants and substitute 
intestinal medication. One promising way of manufacturing such biotech-
nological therapeutic agents is the lyophilisation of single drops or sprays – a 
complex technological approach that still requires research and process layout. 
Besides experiments, numerical flow simulations are capable of providing 
insight into the physics that influence the transport and mass and heat transfer 
related to porous particles. Predicting the corresponding multiphase flows 
requires knowledge of the behaviour of porous particles in comparison to solid 
ones. By performing fully-resolved direct numerical simulations (DNS) of single 
complex particles correlations between particle properties and their fluid 
dynamic behaviour are to be established. 
In this work, the Lattice-Boltzmann method (LBM) is used to simulate the flow 
around virtual lyophilisates and to calculate drag, lift and torque coefficients [1]. 
A future aim is to perform simulations of the sublimation process of frozen spray 
droplets which are numerically realized in form of heterogeneous particles. In a 
first approach, the highly-porous lyophilisates are modelled by creation of 
simplified aggregates consisting of spherical primary particles (Fig. 1, left). This 
base structure is covered by a mutable hull-shaped matrix to represent the 
second phase of the frozen solution of the medical agent which is shrinking due 
to sublimation (Fig. 1). 
 
     
Fig. 1. Flow around a heterogeneous particle with shrinking second phase 
 
This work was supported by Deutsche Forschungsgemeinschaft (DFG grant SO 
204/36-1, SPP 1423). 
[1]  Hölzer A, Sommerfeld M. Lattice Boltzmann simulations to determine drag, lift and torque acting on 
non-spherical particles. Comput Fluids. 2009; 38: 572–589. doi:10.1016/j.compfluid.2008.06.001 
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Numerical methods such as Finite Element Analysis (FEA) or Computational 
Fluid Dynamics (CFD) are considered to be well established technologies in 
industrial design and engineering. While the methodology of numerical 
simulation is fully recognized in conventional industry (e.g. automotive, aviation, 
construction, machinery) even (especially) for critical application, pharma-
industry and biotechnology have just started to carefully consider numerical 
simulation methods as valueable tool to create a sound understanding of their 
processes. The high level of regulation in this specific industry as well as the 
strong drive for evidence based validation (verfication) may have contributed to 
the fact that numerical simulation methods are hardly applied in pharma 
industry and biotech. 
The paper in hand shall demonstrate on typical applications how the CFD 
approach can be applied to design and optimize processes, to create additional 
knowledge about specific process interactions, to provide better understanding 
about correlations between process parameters and product quality, to supply a 
sound data base for process validation and thus to increase process flexibility. 
In four different references various aspects of the CFD methodology are 
discussed. The operational performance of a fermenter is presented with 
specific focus on gas distribution (oxygen) depending on mixer and vessel 
design and on shear stress exposure of the cell culture. Also, a stirred and 
heated storage vessel for thermal sensitive emulsions is investigated. 
Especially the temperature distribution within the products related to the 
temperature of the heating jacket and stirrer parameters shall be analysed. A 
third application considers a very specific freeze technology for protein-buffer-
solutions. The freeze and thaw process is analysed by CFD under specific 
consideration of temperature induced concentration shifts in the protein-buffer. 
Finally a standard vessel-agitator set-up is discussed and strategies for process 
optimizations are presented based on CFD. Based on this specific problem it 
shall be demonstrated how CFD can support process-upscaling from lab to 
industrial size. 
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This contribution describes the dynamic optimization of a pharmaceuticals batch 
dryer. The optimal control problem is based on the control vector discretization 
or single shooting method, thus a non-linear programming (NLP) problem is 
obtained. The target of the open loop optimization problem is the batch time 
minimization and the control variables are the On/Off intervals of the mixer and 
the mixer rotation speed. In order to implement a relevant scenario from 
practical point of view the following constraints are applied: the on and off 
intervals have same duration, the stirrer speed is constant during the entire 
batch drying process and the final moisture specification must be met. Finally, 
an upper limit on the fines fraction in the particle size distribution is set. The 
dryer model [1] consists of a system of partial differential equations coupled to a 
population balance model which describes the breakage process. The 
optimization problem presents several local minima and low gradient regions, 
thus a gradient based method fails to converge to the minimum. Therefore, a 
genetic algorithm-pattern search (simplex) method is used to ensure 
convergence of the optimization problem. The relevance of the work is 
highlighted by recent contributions which deal with the operation optimization of 
this unit operation [2–5]. 
[1]  Kohout M, Stepanek F. Multi-scale analysis of vacuum contact drying. Drying Technol. 2007; 25: 
1265–1273. doi:10.1080/07373930701438741 
[2]  Lekhal A, Girard KP, Brown MA, Kiang S, Khinast JG, Glasser BJ. The effect of agitated drying on the 
morphology of L-threonine (needle-like) crystals. Int J Pharm. 2004; 270: 263–277. 
doi:10.1016/j.ijpharm.2003.10.022 
[3]  Lekhal A, Girard KP, Brown MA, Kiang S, Glasser BJ, Khinast JG. Impact of agitated drying on crystal 
morphology: KCl-water system. Powder Technol. 2003; 132: 119–130. doi:10.1016/S0032-
5910(03)00056-1 
[4]  Simon LL, Hungerbuhler K. Industrial batch dryer data mining using intelligent pattern classifiers: 
Neural network, neuro-fuzzy and Takagi-Sugeno fuzzy models. Chem Eng J. 2010; 157: 568–578. 
doi:10.1016/j.cej.2010.01.018 
[5]  Michaud A, Peczalski R, Andrieu J. Optimization of crystalline powders vacuum contact drying with 
intermittent stirring. Chem Eng Res Des. 2008; 86: 606–611. doi:10.1016/j.cherd.2007.10.005 www.scipharm.at Scientia  Pharmaceutica  567 
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In the pharmaceutical industry spray coating is a frequently used method to 
apply a film layer on the surface of tablets or pellets. The function of coating 
ranges from the controlled release of active pharmaceutical ingredients (APIs) 
to taste masking and coloring. A widely used technique is drum coating, where 
tablets are placed in a rotating drum and the coating liquid is sprayed onto the 
moving tablet bed surface. One of the most central quality attributes is the 
uniformity of coating, both inter-tablet and intra-tablet. Besides experimental 
work [1], numerical simulations have become an extremely important tool in 
process design and development. 
Coater performance depends on a range of different parameters, which could 
be essential for the quality of the final product. In order to quantify the impact of 
different CPPs (critical process parameters) on the related CQAs (critical quality 
attributes), the combination of advanced numerical methods on different scales 
is necessary. In this work we present an innovative approach to analyze, 
understand and optimize important steps of the pharmaceutical tablet coating 
process by means of numerical simulations. The final outcome is the application 
of the developed methods to industry-scale processes. 
Concerning our numerical multi-scale approach, the Discrete Element Method 
(DEM) is used for the simulation of the tablet bed mixing. Furthermore, a 
detailed numerical analysis of the interaction between spray droplets and tablet 
surface is performed with multiphase Computational Fluid Dynamics (CFD) 
methods [2]. On a larger scale, the CFD approach is also adapted to investigate 
the coater internal flow in terms of drying air and liquid spray efficiency.  
Summarizing, the presented combination of simulation methods helps to gain a 
deeper understanding of the spray coating process, providing a further step 
away from trial-and-error towards Quality-by-Design approach. 
[1]  Dubey A, Portillo PM, Muzzio FJ. Study of Tablet Coating Thickness Uniformity Using LIBS, DEM and 
Compartment Modeling. 2008 AIChE Annual Meeting. 
[2]  Suzzi D, Radl S, Khinast JG. Local Analysis of the Tablet Coating Process: Impact of Operation 
Conditions on Film Quality. 2009, Submitted to Chem Eng Sci. 568 Scientia  Pharmaceutica  www.scipharm.at 
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The impact of liquid drops on wetted and dry surfaces is a complex two-phase 
flow phenomenon with high technical relevance especially in surface coating. It 
is also of increasing interest in the development of novel drug dosage forms in 
pharmaceutical engineering. The complex physics after the impact, which is still 
not understood in full detail, has been investigated in numerous experimental 
and analytical studies. Based on dimensional analysis and/or simplifying 
assumptions various semi-empirical correlations and analytical solutions have 
been derived to describe the individual stages of the motion of the liquid (see, 
e. g. [1, 2]). The present work numerically investigates the whole process of the 
liquid spreading after the impact using the CFD software FLUENT. Impact 
velocities and surface wettabilities were varied in the considered cases. It is 
shown that the Volume of Fluid based approach, which has become a standard 
numerical method for two-phase flow simulations, generally captures the typical 
flow features, like splashing (see Fig. 1), qualitatively and quantitatively very 
well. As such the computational results agree very well with the experimental 
data and analytical asymptotic solutions obtained for the individual regimes in 
literature. Notable discrepancies were however observed at the late stages of 
the liquid spreading on dry surfaces, where the outer rim of the liquid lamella 
eventually starts to recede. This deficiency points at the great numerical 
challenge to capture accurately the dynamics at the contact line between the 
liquid, gas, and the solid surface. The strong sensitivity of the incipience of 
liquid receding to the contact physics becomes very evident here. 
 
       
 
Fig. 1. Evolution of the liquid phase (denoted by red area) after drop impact on a wetted surface 
(We=203, Oh=0.005). 
[1]  Yarin AL, Weiss DA. Impact of drops on solid surfaces: self-similar capillary waves, and splashing as a 
new type of kinematic discontinuity. J Fluid Mech. 1995; 283: 141–273. 
doi:10.1017/S0022112095002266 
[2]  Rioboo R, Marengo M, Tropea C. Time evolution of liquid drop impact onto solid, dry surfaces. Exp 
Fluids. 2002; 33: 112–124. doi:10.1007/s00348-002-0431-x www.scipharm.at Scientia  Pharmaceutica  569 
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Magnetoliposomes (MLs) are phospholipid vesicles encapsulating magnetic 
nanoparticles utilised as contrast agents for targeted molecular Magnetic 
Resonance Imaging (MRI). There are different methods of preparation and 
characterization of liposomes containing ultra small paramagnetic iron oxide 
ions (USPIOs) i. e. lipid film hydration method [1] or reverse phase evaporation 
[2]. In this work as magnetic core we have used commercially available dextran 
coated iron particles (Molday-ION, purchased by Bio-Pal, USA), with a colloidal 
size of 30 nm. Liposomes were prepared by thin lipid film hydration method: a 
predetermined mixture of lipids made of phosphatidylcholine, with or without 
cholesterol and small amounts of PEG-ylated lipids (which sterically stabilize 
the liposome reducing their usual rapid uptake from the immune system) was 
dissolved in organic solvent and evaporated to dryness. Then the dry lipid film 
was hydrated with a buffered aqueous solution of different concentration of 
dextran magnetite. The resulting MLs, which were heterogeneous in their size, 
were centrifuged suddenly after the hydration step to remove excess dextran 
magnetite; some MLs were  sonicated before centrifugation with an Ultra 
Sonicator (50 min, 130 Watt) to obtain a homogeneous particle size. Physical 
characterization was performed by dynamic light scattering (DLS) to determine 
the mean particles diameter and the size distribution. These data were 
compared to morphological images obtained by transmission electron 
microscopy (TEM). Chemically, the absolute amount of Fe in MLs was 
determined by a colometric test using potassium thiocyanate (KSCN) as 
reagent. MRI measurements were performed in vitro in agarose gel phantoms 
to evaluate the intensity of the contrast agent on T1 and T2 relaxation time. In 
vivo, the biodistribution and the cleareance of the particles over time were 
studied in mice. MLs have shown a high negative and positive enhancement in 
MRI and due to this strong contrast effect they will be modified for non invasive 
diagnosis of atherosclerotic plaques by targeted molecular imaging. 
[1]  Leszcyznska D, Leszcyznska J, Babincova M, Babinec P. Magnetoliposome composition for targeted 
treatment of biological tissue and associated methods. Patent Application Publication. Pub.No.: US 
2003/0211045 A1. Pub.Date: Nov. 13, 2003. 
[2]  Viroonchatapan E, Ueno M, Sato H, Adachi I, Nagae H, Tazawa K, Horikoshi I. Preparation and 
Characterization of Dextran Magnetite-Incorporated Thermosensitive Liposomes. Pharm Res. 1995; 
12: 1176–1183. doi:10.1023/A:1016216011016 570 Scientia  Pharmaceutica  www.scipharm.at 
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Ultrasound active liposomes currently have gained a lot of interest as 
therapeutic agents for targeted drug delivery. A well known problem is their fast 
clearance from the circulation and thus the short time frame for drug release. 
The use of ultrasound as external trigger for drug release is attractive because it 
can be easily focused and only few adverse effects on the healthy tissue can be 
observed. 
To prolong the blood circulation kinetics the liposome surface can be modified 
with poly(ethylene glycol) (PEG) derivatives to prepare so called ‘Stealth’ 
liposomes[1]. Lin and Thomas described that the PEG content in the liposome 
membrane influences the drug release during ultrasound application [2]. 
A new ultrasound contrast agent composed of dipalmitoylphosphatidylcholine or 
distearoylphosphatidylcholine and varying concentrations of polyethyleneglycol-
40stearate was prepared using the thin-film hydration method. It was 
demonstrated that concentrations of 1 mol% and 10mol% polyethyleneglycol-
40stearate show very good ultrasound activity. This result was unexpected due 
to the small size of only 100–200nm. 
The aim of this study was to determine the physico-chemical properties and the 
structural behavior of these contrast agents. Therefore 
31P-NMR measure-
ments, AFM investigations and TEM images were correlated. A combination of 
these methods should enable us to distinguish between organisations such as 
micelles, SLN and liposomes. 
The authors would like to thank the DFG “Forschergruppe Nanohale 695” for 
support. 
[1]  Bendas G, Krause A, Bakowsky U, Vogel J, Rothe U. Targetability of novel immunoliposomes 
prepared by a new antibody conjugation technique. Int J Pharm. 1999; 181: 79–93. 
doi:10.1016/S0378-5173(99)00002-2 
[2]  Lin HY, Thomas J. PEG-Lipids and Oligo(ehtylene glycol) Surfactants Enhance the Ultrasonic 
Permeabilizability of Liposomes. Langmuir. 2003; 19: 1098–1105. doi:10.1021/la026604t 
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Specially engineered drug particles can solve solubility and formulation 
problems, which are major challenges for the pharmaceutical industry. Particle 
size reduction of poorly water soluble drugs results in increased dissolution rate 
and higher bioavailability or better processability as demonstrated in previous 
studies [1, 2]. High-pressure homogenization can be used to decrease particle 
size, since it induces cavitation forces and causes highly localized increase in 
temperature and pressure within the fluid, resulting in decrease of particle size 
and inhibition of agglomeration. The current study is focused on properties 
inherent to particle engineering as well as methods for production and 
characterization of micro- and nanocrystals. The meloxicam, a low molecular 
weight analgetic for oral administration, exhibits a slow dissolution, therefore, it 
was formulated as micro- or nanosized particles by high-pressure 
homogenization. The samples were freeze-dried and characterized regarding 
particle size, morphology, structural analyses (DSC, XRPD) and in vitro 
dissolution rate. The final formulations were free of organic solvent and 
contained micro- (4–8 μm) or nano-sized (400–1000 nm) meloxicam crystals. 
Meloxicam in vitro dissolution rate was significantly improved and its particle 
size was found to be dependant on stabilizers used. To conclude, the new 
meloxicam formulations can potentially expand its application also to alternative 
administration routes (e. g. pulmonary and intranasal).  
This work was supported by TÁMOP-Hungary research project: Development of 
teranostics in cardiovascular, metabolics, and inflammatory diseases (TÁMOP-
4.2.2-08/1-2008-0013). 
[1]  Ambrus R, Naghipour-Amirzadi N, Sipos P, Szabó-Révész P, Weisbrod W. Effect of 
sonocrystallization on the habit and structure of Gemfibrozil crystals. Chem Eng Technol. 2010; 33: 
827–832. doi:10.1002/ceat.200900568 
[2]  Ambrus R, Kocbek P, Kristl J, Šibanc R, Rajkó R, Szabó-Révész P. Investigation of preparation 
parameters to improve the dissolution rate of poorly soluble meloxicam. Int J Pharm. 2009; 318: 153–
159. doi:10.1016/j.ijpharm.2009.0700 572 Scientia  Pharmaceutica  www.scipharm.at 
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The availability and use of appropriate Process Analytical Technology (PAT) is 
fundamental to achieving the transformed style of pharmaceutical manufacture 
that is envisaged by the regulators. Implementing the knowledge-driven, risk-
based approach to development and manufacture described in ICH Q8, Q9 and 
Q10 Guides, and adopting more efficient, modern operating practices, depends 
on being able to reliably identify, analyze and control those parameters that 
dictate pharmaceutical performance. This paper examines the potential 
contribution of laser diffraction particle sizing technology within this context, 
focusing on the use of industrially proven on-line solutions for real-time 
measurement and automated process control. 
Particle size has a controlling effect on the behaviour of many pharmaceutical 
products, often influencing critical to quality parameters such as dissolution rate, 
bioavailability and product stability. Where this is the case, the robust and 
proven technique of particle sizing by laser diffraction has for many become the 
method of choice. Non-destructive, with measurement rates sufficiently rapid for 
real-time monitoring, laser diffraction transitions easily, from the laboratory 
through to on-line measurement within the pilot plant, or in a manufacturing 
environment. With on-line analysis in place, the design, optimization and control 
of unit operations such as granulation, spray drying and, perhaps most 
importantly, milling becomes simpler and much more effective. Case studies 
illustrate this, the most compelling describing the use of on-line laser diffraction 
technology to fully automate control of a mill such that the particle size of the 
exiting active is maintained within specification despite variations in feed quality.  
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The aim of Process Analytical Technology (PAT) is to gain deeper insight in 
pharmaceutical manufacturing processes, replacing empirical approaches by 
knowledge-based procedures. A detailed understanding of the key parameters 
of a process and their impact on the product quality allows companies to “build 
in quality” instead of “testing it into the final product”. From this point of view, 
PAT has to be tailored for a direct implementation to manufacturing lines to 
measure in real-time the key parameters of the process.  
Here, we present results on real-time quantitative in-line monitoring of powder 
mixing processes by near-infrared (NIR) spectroscopy [1,  2]. Spectral data 
collection and data analysis was performed in real-time based on partial least 
squares models developed via dynamic calibration. Different strategies are 
followed: I) Application of a single reflection probe to determine the mixing end-
point. II) A novel multiple reflectance probe measurement system for a spatially 
resolved monitoring of the powder flow kinetics within a blender. The 
parameters from the mixing process are linked to keyparameters of powders, 
obtained from rheometric investigations based on experimental design. 
Beside the batch processes monitored here with NIR spectroscopy, we also 
introduce hyper spectral imaging for monitoring fast continuous processes and 
non-invasive product quality analysis of solid dosage forms. 
[1]  Koller DM, Posch A, Hörl G, Voura C, Radl S, Urbanetz N, Fraser SD, Tritthart W, Reiter F, 
Schlingmann M, Khinast JG. Continuous Quantitative Monitoring of Powder Mixing Dynamics by Near-
infrared Spectroscopy. Powder Technol. 2010; submitted. 
[2]  Remy B, Glasser BJ, Khinast JG. The effect of mixer properties and fill level on granular flow in a 
bladed mixer. AIChE J. 2010, 56: 336–353. doi:10.1002/aic.11979 574 Scientia  Pharmaceutica  www.scipharm.at 
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Near-infrared spectroscopy (NIRS) is a rapid and nondestructive analytical 
method. The use of near-infrared spectroscopy in the pharmaceutical industry 
has been rapidly increasing over the past decade, with particular interest in the 
analysis of solid dosage forms, such as tablets and capsules [1]. This article 
describes use of NIR spectroscopy to determine of content the active 
pharmaceutical ingredient (metformin hydrochloride) in tablets, as well as 
strength tablets. Our goal is to create a necessary basis of spectral data and 
develop an optimal chemometric models that will later be transferred and used 
for monitoring the process. The calibration set was made up of 100 laboratory 
and 180 production samples in which the content of the active ingredient varied 
from 90 % to 110% of the declared value. The set of calibration samples, used 
for determination of the tablet hardness, included 70 laboratory and 70 
production samples, which were compressed using four levels of compression 
force. The API content is determined by the validated HPLC method, while 
Erweka hardness tester was used to determine tablet hardness. NIR spectra 
analysis by using method of partial least squares [2]. The best result for drug 
content determination was obtained for the raw spectrum, where the coefficient 
of correlation for calibration model was 0.99945, RMSEC 0.552, and RMSEP 
0.570, with seven factors used. The model which gave the best results for the 
tablet hardness determination was obtained by second-derivative spectra 
(coefficient of correlation: 0.99616, RMSEC: 0.506 and RMSEP: 0.841).  
According to the obtained results, it was concluded that both models ensured a 
high coefficient of correlation as well as low level of error of the calibration 
model and prediction. It can be concluded that NIR spectroscopy, a rapid and 
nondestructive technique, is a powerful tool that can be easily implemented, 
with appropriate technical solutions, in the production process, thus ensuring its 
on-line or in-line monitoring.  
[1]  Reich G. Near-infrared spectroscopy and imaging: Basic principles and pharmaceutical applications. 
Adv Drug Deliv Rev. 2005; 57: 1109–1143. doi:10.1016/j.addr.2005.01.020  
[2]  Adams MJ. Chemometrics in Analytical Spectroscopy, Royal Society of Chemistry, Cambridge, UK, 
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Background: The use of nano-sized materials (NMs) offers exciting new options 
in technical and medical applications. Adverse effects on cells and organs, 
however, have also been reported. It is known that NMs may interfere with 
conventional assays. It may be suspected that inter-cell line differences in the 
sensitivity to NMs also exist. NMs may also interact physicochemically with 
plasma membranes. Cells in suspension, where a relatively large area is 
exposed, may therefore react different from adherent cells. As NMs by 
interaction with the replicative machinery may inhibit proliferation, also the 
proliferation rate (length of the doubling time) may be an important parameter.  
Methods:  To assess the effect of the medium 20–1000 nm large carboxyl 
polystyrene particles (CPS) were tested in the presence of different amounts of 
fetal bovine serum. Potential interference was evaluated by testing in the 
cytotoxicity screening assays WST-1, MTT, MTS, Neutral Red, Sulforhodamin 
B, leucine incorporation and ATP content. IC50 concentrations were compared 
between 20 different cell lines.  
Results: The size of small (20–60 nm) CPS increased markedly from medium 
with 0% to 10% FBS; for larger CPS only minimal differences were seen. 20 nm 
CPS in medium with 0% FBS acted cytotoxic in all cell lines. 20 nm CPS in 5% 
and 10% FBS and larger CPS in all media were only minimally cytotoxic to non-
phagocytic cells. In phagocytic cells also CPS of ≥ 500 nm acted cytotoxic. Half 
maximal inhibition concentrations (IC50) in a given cell line did not differ 
markedly between the screening assays but varied more than 10 times between 
the cell lines. IC50 values were significantly lower in suspension cells. Large 
cells and human cell lines with long doubling times were more resistant to the 
cytotoxic action of 20 nm CPS.  
Conclusions:  In addition to medium composition, growth characteristics, 
proliferation and cell size of the cell line used for testing may influence the IC50 
values of NMs. Cells in suspension are especially sensitive to the cytotoxic 
action of small carboxyl polystyrene nanoparticles. 
This work was supported by the FP6 European integrated project 
“NanoBioPharmaceutics”, NMP4-CT-2006-026723 and by the RPC project 
‘Nano-structured Materials for Drug Targeting, Release and Imaging’. 576 Scientia  Pharmaceutica  www.scipharm.at 
Presented at the 8
th Central European Symposium on Pharmaceutical Technology, 
September 16
th–18
th 2010, Graz, Austria. 
Conference abstract LNT02 
Development of Solid Lipid Nanoparticles for 
Praziquantel Delivery: Particle Size 
Characterization and Cell Toxicity Assessment 
A. L. R. SOUZA 
1,2, T. ANDREANI 
2, S. DOKTOROVOVÁ 
3,  
A. M. SILVA 
2,4, E. B. SOUTO 
5, M. P. D. GREMIÃO 
1 
1  Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, UNESP, Araraquara, 
Brazil 
2 Department of Biology and Environment, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal 
3 Centre of Genomics and Biotechnology, IBB/CGB-UTAD, Vila-Real, Portugal 
4 Centre for Research and Technology of Agro-Environmental and Biological Sciences, Vila Real, Portugal 
5 Department of Pharmaceutical Technology, Faculty of Health Sciences, UFP, Porto, Portugal 
E-mail: analuizars@yahoo.com.br (A. L. R. Souza) 
Sci Pharm. 2010; 78: 576        doi:10.3797/scipharm.cespt.8.LNT02 
Praziquantel (PZQ) is a drug active against all species of Schistosoma and it is 
the drug of choice for the treatment of schistosomiasis [1]. Due to its low water 
solubility and risk of parasite resistance or tolerance to PZQ, it would be useful 
to develop a novel pharmaceutical product that could increase its therapeutic 
efficacy and improve the bioavailability. Solid lipid nanoparticles (SLN) combine 
the advantages of different colloidal carriers and also avoid some of their 
disadvantages in relation to the stability and possibility of large scale 
production. Thus, the aim of this work was to develop SLN containing PZQ 
(SLN-PZQ) and evaluate the cytotoxicity in the HepG2 cell line. The SLN were 
produced by a modified of the oil-in-water microemulsion method [2] using 
stearic acid as lipid core and poloxamer 188 as surfactant. The PZQ was 
incorporated in lipid core for the production of SLN-PZQ. Particle size was 
measured by dymamic light scattering (DLS) and the electrophoretic mobility 
was measured by laser Doppler anemometry. The cytotoxicity of PZQ 
(dissolved in ethanol) and SLN-PZQ was examinated in the HepG2 cell line 
using AlamarBlue assay [3]. The prepared SLN-PZQ had a mean particle size 
of 480.4nm with a zeta potential of −36.5mV. In HepG2 cell cultures, the tested 
SLN-PZQ suggested a decreased toxicity of the drug when delivered by SLN, in 
comparison to a conventional PZQ solution of similar concentration. The degree 
of toxicity was shown to be dose-dependent. 
This work was supported by CAPES. 
[1]  Cioli D. Chemotherapy of Schistosomiasis: An Update. Parasitol Today. 1998; 14: 418–422. 
doi:10.1016/S0169-4758(98)01323-4 
[2]  Heydenreich AV, Westmeier R, Pedersen N, Poulsen HS, Kristensen HG. Preparation and purification 
of cationic solid lipid nanospheres – effects on particle size, physical stability and cell toxicity. Int J 
Pharm. 2003; 254: 83–87. doi:10.1016/S0378-5173(02)00688-9 
[3]  Miura N, Matsumoto Y, Miyairi S, Nishiyama S, Naganuma A. Protective effects of triterpene 
compounds against the cytotoxicity of cadmium in HepG2 cells. Mol Pharmacol. 1999; 56: 1324–1328. 
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Many current dermatological preparations, sunscreens and other cosmetics, 
contain nanosized particles (NPs), which were observed to be rapidly inter-
nalized by keratinocytes [1]. Besides their ability to enter into cells, NPs can be 
responsible for higher toxicity compared to bigger particles, mainly due to their 
larger surface area and enhanced chemical reactivity. Application of NPs 
increase the risk of cell damage and consequently cause alterations in mito-
chondria, actin filaments, cell membranes, etc., usually resulting in diminished 
cell functions or even cell death [2]. Despite the fact that ZnO and/or TiO2 NPs 
are frequently used, only few long-term toxicological studies are available. Our 
research was focused on long-term investigations, where the effects of 
repeated application of ZnO and TiO2 NPs on keratinocytes were evaluated. 
The preliminary short-term experiments showed no adverse effects of ZnO and 
TiO2 NPs on viability and morphology of keratinocytes in concentrations up to 
15 μg/ml. Furthermore, TiO2 NPs did not significantly affect cell viability as well 
as cell growth in concentrations up to 100 μg/ml. Oppositely, ZnO NPs 
decreased cell viability in concentrations above 20 μg/ml sharply, and caused 
detachment of keratinocytes. Thus, the keratinocytes can survive short-term 
exposure to low concentrations of ZnO and TiO2 NPs, however, question 
regarding cell ability to maintain essential functions during their life span arises. 
Therefore, the concentration that did not show any cytotoxicity in short-term 
experiments was used for long-term investigations.The results after 3 months 
continuous treatment with 10 μg/ml NPs showed no significant changes in 
generation of reactive oxygen species (ROS) compared to untreated cells. 
Microscopical observation of cells continuously exposed to TiO2 indicated 
unchanged cell surface and presence of endosomes filled with TiO2 NPs, which 
were enlarged compared to endosomes of untreated control cells. Contrary, 
exposure to ZnO caused significant decrease in cell number as well as appear-
ance of dense nuclei and disappearance of visible actin filaments, elevated 
ROS levels and decreased mitochondrial activity, indicating oxidative stress as 
a main cause for cytotoxicity of ZnO NPs. To sum up, the results indicate that 
the right selection of NPs is crucial for formulation of safe dermal products. 
[1] Teskač K, Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J 
Pharm. 2010; 390: 61–69. doi:10.1016/j.ijpharm.2009.10.011 
[2]  Nel A, Xia T, Mädler L, Li N. Toxic Potential of Materials at the Nanolevel. Science. 2006; 311: 622. 
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Introduction: The oral cavity acts as a complex barrier and displays the first 
main hindrance against uncontrolled uptake of a variety of substances. The oral 
mucosa represents 60% of the total surface area within the oral cavity, offers a 
good opportunity for drugs to be absorbed and shows a 4 to 4.000 times greater 
permeability than the skin.The barrier function of this tissue is mainly 
guaranteed by i) the saliva, ii) the mucus layer, iii) the cell junctions in the 
epithelium and iv) the membrane coating granules. However, as the 
permeability of drugs through the oral mucosa is limited, new delivery carriers 
have to be developed. Nanostructured materials (NMs) are small enough to 
overcome this tissue. Within the development of such nano-carriers, the efficacy 
as well as the safety are important factors that cannot be neglected. Currently, 
no standardized physiological in vitro models, evaluating the permeability, 
transport route and toxic effects of NMs are available. Methods:  NMs 
(polystyrene particles (PS), silver particles Ag)) were primarily characterized in 
terms of size and surface charge in physiological media. The penetration of the 
particles was investigated through excised buccal mucosa from pig. The in vitro 
permeability studies were carried out with Franz diffusion cells. It is a fact that 
the diffusion barriers in the buccal mucosa are only functional within living cell 
layers. Therefore, the viability (MTT) and the structural integrity of the 
membrane (methylene blue/PBS with and without EDTA) were investigated. 
The transport studies were carried out with Transwells® and the Trans-
Epithelial Electric Resistance (TEER) was measured. The particle uptake into 
the cells was recorded with fluorescence/electron microscopy and the cell 
damage was evaluated. Results: The results demonstrate that the permeability 
of the particles depends on the size, surface charge, hydrophobicity and particle 
concentration. Particles in sizes of 20 nm (PS) and 35 nm (Ag) permeated the 
mucus layer and penetrated in the stratum superficiale of the top third region of 
the epithelium. They did not affect the tight junctions and were taken up by the 
cells. The cellular uptake correlated with the cell damage. Particles in sizes of 
150 nm (Ag) and 200 nm (PS) aggregated in the saliva, were entrapped in the 
mucus layer and could not enter the top third region of the epithelium. 
Additionally, they also did not affect the tight junctions and no cellular uptake 
could be recorded. Conclusion: Independent from the material small (20–35 nm) 
NMs showed a much higher penetration than larger (150–200 nm) NMs. www.scipharm.at Scientia  Pharmaceutica  579 
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Studies on nasal epithelial models are important to develop vehicles for 
systemic nasal drug delivery, and also for targeting drugs to brain via the nasal 
route. RPMI 2650 human nasal septum carcinoma cell line was used in our 
experiments as an in vitro cell culture model for toxicity and permeability 
assays.  
For toxicity tests cells were cultured in 96-well plates, and MTT dye conversion 
and lactate dehydrogenase release were determined after treatments. For 
permeability tests RPMI 2650 cells were cultured on collagen-coated Millipore 
CM inserts (hydrophilic PTFE membranes, pore size: 0.4 µm, surface 4.2 cm
2) 
in 6-well plates. Fluorescein was selected as a marker of paracellular 
permeability, and TEER and Papp were measured.  
RPMI 2650 cells passaged at high cell density grew as confluent multilayers on 
inserts. To induce barrier properties several treatments and culture conditions 
were tested. The effects of serum, hydrocortisone, cAMP and air-liquid interface 
on RPMI 2650 cell layers were examined. Hydrocortisone and cAMP increased 
the tightness of the nasal epithelial barrier, and induced the expression and 
junctional localization of claudin-1, claudin-4, ZO-1, and β-cathenin visualized 
by immunohistochemistry and confocal microscopy. The changes in cell and 
junctional morphology were confirmed by electron microscopy. The resistance 
of the monolayers reached 240 ± 13 Ωcm
2, and Papp of 2.7 ± 0.2 10
−6 for 
fluorescein indicating a barrier typical for nasal epithelium. The model was used 
to test the non-toxic nasal doses of absorption enhancers Tween 80, 
Cremophor RH40, Transcutol P, and water soluble sucrose esters and to 
determine their effects on paracellular permeability. Tween 80 and Cremophor 
RH40 decreased TEER by 50 % and significantly increased Papp values of 
RPMI 2650 layers. 
We have successfully established a human in vitro nasal epithelial model that 
can be used to study the effects of absorption enhancers and their mode of 
action. 
This work was supported by TÁMOP-Hungary research project: Development of 
teranostics in cardiovascular, metabolic, and inflammatory diseases (TÁMOP-
4.2.2-08/1-2008-0013). 580 Scientia  Pharmaceutica  www.scipharm.at 
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Introduction:  Nanotechnologies and Nanomedicine are promising fields of 
scientific research. Experts expect a huge economic and social impact from 
Nanotechnologies and Nanomedicine in the next decades. New properties 
associated with size smaller than 100 nm opens a new world of applications. At 
the same time, possible toxicological aspects associated with nanotechnologies 
are being discussed in the scientific community. Nanotoxicity, possibly resulting 
from altered chemical and physical behaviour of nanoparticles compared to bulk 
material, is a major concern nowadays. These phenomena are believed to be 
related to the extreme high specific surface area and altered electrochemical 
properties of nanoparticles. The investigation of nanomaterials in terms of their 
toxicological behaviour is an extremely multidisciplinary challenge. Toxicology 
of non-nano chemicals is a well established procedure. Unfortunately, Nano-
toxicology is quite more complicated and standard protocols in Toxicology can 
not be used. Nanomaterials have to be investigated in detail for different 
parameters like size, size distribution, shape, charge, etc. Furthermore, 
interaction with different matrices like blood, interstitial fluid, buffers, etc. 
influences significantly nanomaterials like, agglomeration, size distribution, 
charge, etc. In consequence, nanotoxicology needs new standardised protocols 
which are able to deal with the extreme complexity of nanomaterials and their 
toxicological behaviour! 
Focus: To build a national contact point for nanotoxicology, the BioNanoNet as 
a network company, has initiated the build up of the European Center of Nano-
toxicology (www.euro-nanotox.at). This virtual center unites all Austrian Experts 
in the field of Nanotoxicology and helps to develop standardized methods. 
EURO-NanoTox initiates research projects together with its members and is 
links Austrian activities in the field of nanotoxicology to European activities. 
Within this contribution the European Center for Nanotoxicology will be 
presented. The general strategy of a stepwise approach to investigate 
nanomaterials in respect of their potential toxic properties will be shown. 
Furthermore, some details for the investigation of skin penetration of quantum 
dots will be addressed. www.scipharm.at Scientia  Pharmaceutica  581 
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Powder mixing is crucial for many processing stages within the pharmaceutical, 
catalysis, food, cement, and mineral industries, to name a few. A significant 
problem hindering process design is the paucity of information about the effects 
of changing process parameters on mixing efficiency, especially in the case of 
continuous mixing.  
The main target of this talk is to highlight continuous mixing and to examin the 
effects of different process and design parameters. Interestingly, continuous 
processing has been utilized extensively by petrochemical, food, and chemical 
manufacturing but has yet to reach the pharmaceutical industry to a meaningful 
extent. Recent research efforts indicate that a well-controlled continuous mixing 
process illustrates the capability of scale-up and ability to integrate on-line 
control ultimately enhancing productivity. 
In this talk we will decribe the use of engineering methodologies to design 
continuous pharmaceutical manufacturing systems for solid dose products. We 
will examine the performance of gravimetric feeders and continuous mixers, and 
their integrated dynamics, and develop  guidelies for the optimal design and 
operation of the integrated system. Variance components will be characterized, 
and the monitoring of performance using PAT tools will be discussed.  
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Introduction: Xanthan (XAN) is a well known negatively charged biopolymer that 
adopts different conformations in media, which are still poorly understood. XAN 
tablets in contact with water hydrate, forming a gel layer that regulates the drug 
release rate [1]. The hypothesis was that XAN molecular structure influences 
the drug release from matrix tablets. Thus, detailed studies on molecular as well 
as on macro-scale level were performed. 
Experimental: To determine XAN molecular conformations, its solution in water 
at pH 7.0 or 1.2 was deposited on freshly cleaved mica, dried and images were 
taken in air using tapping mode AFM. In order to determine Young’s modulus 
and investigate properties of single XAN molecule, nanoindentation as well as 
nanofishing were performed. Ingress of media into XAN tablet, gel structures 
and drug release were studied by NMR and MRI, oscillatory rheometer and 
dissolution USP Apparatus II.  
Results and discussion: Our results reveal that XAN adopts single chain 
conformation in water at pH 7.0, whereas at 1.2 double stranded structures are 
formed. This was confirmed by AFM images as well as by calculated 
parameters: persistence length of XAN in water was 210.37 compared to 
116.83 in pH 1.2. Young modulus of XAN film in water was lower (1.52 GPa) 
compared to pH 1.2 (1.94 GPa). Higher rigidity of XAN films at pH 1.2 was 
further confirmed by formation of XAN gels, where elastic G’ and loss G’’ moduli 
were higher in the whole deformation range. Double stranded molecules form 
more cohesive gels, while single stranded are more flexible, due to the higher 
hydration of negatively charged polymer. MRI results proved much higher 
hydration and consequently the swelling of XAN tablets at pH 7.0 than at 1.2 
and the thicker gel layer as well. Surprisingly, drug release in pH 1.2 media was 
faster regardless to firmer gel structure.  
Conclusion: High rigidity and low hydration of XAN matrix in pH 1.2 are the 
consequence of XAN molecular structure regulating drug diffusion in tablets.  
[1]  Mikac U, Sepe A, Kristl J, Baumgartner S. A new approach combining different MRI methods to 
provide detailed view on swelling dynamics of xanthan tablets influencing drug release at different pH 
and ionic strength. J Control Release. 2010; 145: 247–256. doi:10.1016/j.jconrel.2010.04.018 www.scipharm.at Scientia  Pharmaceutica  583 
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Dry powder coating is a relatively new technique to coat substrates without the 
use of any organic solvent or water. The film forming polymer is applied as a 
powder to the cores to be coated leading to reduced process times [1]. 
Additionally, excipients like plasticizers, preferably in liquid form, are often 
needed to soften the polymer in order to get a functional film. A curing step is 
sometimes necessary to achieve film formation depending on the 
characteristics of the polymer used. One critical parameter in dry powder 
coating is the coating efficiency which describes how much of the applied 
coating material actually adheres to the cores. Therefore, another main task of 
the excipients used is to enhance the adhesion of polymer powder. The aim of 
this work was to evaluate excipients, like plasticizers and polymers, regarding 
their suitability for dry powder coating. 
Dry powder coating was performed in a rotary fluid bed (GPCG1.1, Glatt, 
Binzen, Germany). Polymer powder and liquid were fed simultaneously via a 
three-way nozzle to the fluid bed. Coating efficiency was calculated by dividing 
the mass of adherent coating material by the mass of applied coating material. 
Theophylline pellets were used as cores and ethylcellulose, hydroxypropyl-
methylcellulose acetate succinate (HPMCAS) or Eudragit RS
® as coating 
polymer. Various liquids were characterized with respect to several properties, 
like viscosity, spreading behavior and droplet size. Coated pellets were 
investigated via dissolution testing and scanning electron microscopy before 
and after curing steps to evaluate whether film formation was achieved. 
The spreading behavior of the liquids seems to be one key factor affecting the 
coating efficiency. It can be investigated by measuring contact angles of liquids 
on the polymer or predicted by calculating surface energies. However, there are 
still other parameters impacting the coating efficiency of the process like 
viscosity of the liquid, which influences on the one hand the kinetic of spreading 
as well as the droplet size generated by the spraying nozzle. The film forming 
properties of the polymers used were very different. Using ethylcellulose a 
curing step was required to obtain dense films whereas Eudragit RS
® formed 
films without any curing. 
[1]  Kablitz CD, Harder K, Urbanetz NA. Dry coating in a rotary fluid bed. Eur J Pharm Sci. 2006; 27 (2006) 
212–219. doi:10.1016/j.ejps.2005.10.001  
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Coated pellets offer several advantages related to safety and effectiveness of 
the medicinal product such as reproducibility of gastric emptying and of 
absorption, and predictable plasma levels with lower probability of dose 
dumping due to modified release [1,2]. Layered pelletizing involves a process in 
which drug in solution, dispersion or powdered form is loaded onto inert starting 
cores. Starter inert cores have several benefits, such as they serve as nuclei 
with standardized shape, therefore the product shows more exactly defined 
surface for functional coating [3]. 
The objective of this study was to investigate the effects of formulation and 
manufacturing parameters on the pellet quality after the layering and coating 
process applying 3 types of inert core materials (sugar, microcrystalline 
cellulose, and isomalt). An additional objective was to investigate and compare 
the effect of the core material on the in vitro drug release of water soluble and 
poorly water-soluble drugs when they were coated with a permeable polymer 
membrane. 
The drug layering and coating process were followed by non-destructive tests 
such as image analysis and NIR spectroscopy. Flowability, hardness, friability, 
wettability and morphology of starting cores as well as of finished products were 
investigated. 
According to the non-destructive analysis and physical tests, all pellets 
manufactured from different core materials demonstrated satisfactory quality 
attributes. Since the type of inert core material may significantly influence the 
dissolution profile, the solubility characteristics of both the drug and core 
material should be considered.  
[1]  Chopra R, Alderborn G, Podczeck F, Newton JM. The influence of pellet shape and surface properties 
on the drug release from uncoated and coated pellets. Int J Pharm. 2002; 239: 171–178. 
doi:10.1016/S0378-5173(02)00104-7 
[2]  Vitková Z, Vitko A. An evaluation of absorption using an adaptive model. Pharmazie. 1993; 48: 362–
364. PMid:8327564 
[3]  Kállai N, Luhn O, Dredán J, Kovács K, Lengyel M, Antal I. Evaluation of drug release from coated 
pellets based on isomalt, sugar, and microcrystalline cellulose inert cores. AAPS PharmSciTech. 
2010; 11: 383–391. doi:10.1208/s12249-010-9396-x www.scipharm.at Scientia  Pharmaceutica  585 
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Hot Melt Extrusion, proven state-of-the-art technology in the field of plastics, is 
becoming increasingly important in the pharmaceutical industry. In the Hot Melt 
Extrusion process, the polymer is processed above the glass transition 
temperature to mix the active component with the thermoplastic binder and / or 
the polymer on a molecular level.  
The most significant benefits of HME processing are the absence of water and 
solvents, which leads to fewer processing steps and lower manufacturing costs. 
In addition the short residence time is beneficial for many heat- and shear 
sensitive drugs and the free volume in the twin screw gives the processor the 
opportunity to devolatilise the compound in a controlled and reproducible 
environment. 
Because of their excellent mixing behaviour and the degassing possibilities, co-
rotating twin-screws are particularly suitable for Hot Melt Extrusion. The 
modular concept of the Twin Screw Extruder enables the individual adaptation 
of the processing section to the different requirements. Individual steps such as 
dispersive mixing, degassing and pressure build-up take place very effectively 
in this way. 
The closely intermeshing screws with their tight, self-wiping profiles eliminate 
dead zones over the whole length of the process section. The effect: 
consistently higher degree of process reliability and optimal self-cleaning. 
Coperion has references in the pharmaceutical field for twin screw extruders in 
sizes from 18 to 70 mm screw diameter.  
Typical applications for Coperion’s twin screw extruders ZSK: 
–  Hot Melt Extrusion 
–  Production of Transdermale Adhesives  
–  Extrusion of Micro-Pellets  
–  Production of Drugs with Delayed Ingredient Release 
–  Low-Temperature Melt Extrusion 
– Potent-Extrusion 
– Co-Extrusion 586 Scientia  Pharmaceutica  www.scipharm.at 
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The control of particulate processes and their understanding can be improved 
by modern measuring techniques. The paper describes the optical probe 
system Parsum  IPP  70 as an example of the modern measuring techniques 
which is based on the spatial filtering technique (SFT). Measuring principles are 
the fibre-optical spatial filtering velocimetry and the fibre-optical spot scanning in 
order to determine simultaneously the size and the velocity of particles. 
Therefore the measured particle size distributions are chord length distributions 
which can be recalculated. A calibration is not necessary.  
The Parsum  IPP  70 is a compact and highly robust measuring system for 
application as an in-line particle size analyzer for processes involving larger 
particulate sizes up to 6000 µm. It allows a data rate up to 20,000 particles per 
second and the system can track continuously a large variety of process 
parameters. Different options of the measuring system are available: tube 
length up to 4 m, air supply system for dispersion and cleaning, comprehensive 
software support, Ex-Zones and pharma solutions. 
The application is given for grinding/dosing, agglomeration, fluidized bed 
processes, mixing and coating, sieving, wet and dry granulation, spray drying. 
The Parsum IPP 70 is a powerful tool for process control of fluid bed granulation 
in pharmaceutical industry. The advantages are: increase of process 
transparency, short response time in the event of process disturbances, 
continuous control of product quality, full feedback control for automated 
solutions, no need of samples and laboratory analysis. Results are given by 
Petrak et al. [1]. Examples show also the ability to prove the model goodness of 
a fluid bed process by using IPP 70 in-line-SFT [2–4]. 
[1]  Petrak D, Dietrich S, Eckardt G, Köhler M. In-line particle sizing for process control by an optical probe 
based on the spatial filtering technique (SFT). Proceedings CD World Congress on Particle 
Technology 2010; Nürnberg. Germany. 
[2]  Schmidt-Lehr S, Moritz H-U, Jürgens KC. Online Control of Particle Size during Fluidised Bed 
Granulation. Pharm Ind. 2007; 69: 478–484. 
[3]  Närvänen T, Lipsanen T, Antikainen O, Räikkönen H, Yliruusi J. Controlling granule size by 
granulation liquid feed pulsing. Int J Pharm. 2008; 357: 132–138. doi:10.1016/j.ijpharm.2008.01.060 
[4]  Närvänen T. Particle Size Determination during Fluid Bed Granulation 2009; Diss. Faculty of 
Pharmacy of the University of Helsinki. www.scipharm.at Scientia  Pharmaceutica  587 
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To establish a micro fluidic system that covers the whole production process of 
drug-loaded solid lipid nanoparticles especially high pressure emulsification and 
dispersion processes must be taken into account. The advantages of micro 
fluidic systems in a continuous production imply a high surface-to-volume ratio 
(material and energy transfer) and a narrow residence time distribution 
(homogeneously defined stresses). Detailed investigation is needed for process 
understanding and to improve micro channel geometries. 
The micro fluidic geometries were designed to selectively expose product flows 
to different main break-up mechanisms (shear stress, elongational stress, 
turbulent stress, particle-particle and particle-wall impacts). Within these groups 
structural modifications were carried out to evaluate their influence on 
emulsification and dispersion efficiency. 
Two formulations (to simulate the dispersion and emulsification process, 
respectively) were exposed to the specified micro channel geometries (including 
channel height variation) at different pressures, optionally using multiple 
homogenisation cycles in addition. 
The emulsification process in general shows a decrease in particle size by 
elevated pressure and higher number of cycles, as expected. Regarding the 
pressure drop, straight or bent channel geometries show a much lower break-
up efficiency compared to either orifice-like or Y-shaped geometries. The latter 
two types over all show comparable efficiencies. Applying minor structural 
modifications to several geometries results in significant differences in particle 
size. As an example, a cascading quadruple orifice geometry shows 
significantly smaller particle sizes when the flow first interacts with the smallest 
orifice in comparison to passing the smallest orifice at the end. 
The dispersion of solid particles (hydrophilic alumina Alu C) shows similar 
results although the drop in particle size is less pronounced in these 
experiments. This is due to the high binding forces between primary particles. 
The authors gratefully acknowledge the DFG for financial support of the DFG 
research group 856 “Mikrosysteme für partikuläre Life-Science-Produkte“ 
( ). 
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A pharmacokinetic (PK) model describes the absorption, distribution, 
metabolism and excretion of a pharmaceutical, thus providing, once properly 
validated, quantitative predictions of the consequences of various dosing 
regimens. Pharmacological activity might be linked to properties of a time 
course for a particular compartment (such as half-life or area-under-curve, 
AUC), or directly modelled by coupling the PK model with a pharmacodynamic 
(PD) model of the physiological effect of the agent. 
Due to the high replication and mutation rates of the human immunodeficiency 
virus (HIV), which ultimately results in strains resistant to any single agent, a 
multiple-agent strategy has to be adopted. Highly active anti-retroviral therapy 
(HAART) uses two or more agents that target different components of the HIV 
replication cycle, but these agents typically produce adverse side effects in 
patients. A number of authors have applied techniques from nonlinear control to 
this problem, but in general the explicit link between the drug dose and the 
physiological effect, via the PK, is neglected so that the controls derived are 
continuous in time. In [1] the control problem is addressed via feedback 
linearization applied to a PD model of HIV dynamics. A single-compartment PK 
model is then used to estimate a dosing regime that gives rise to the required 
continuous control law. 
In [2] a fixed-point approach was taken to determine the doses required to 
obtain a particular AUC or target profile. Although a constructive method is 
shown for determining the required dosing scheme, full solution trajectories and 
their integrals are required. An iterative method for constructing the dosing 
regime is proposed here that provides the fixed-point solution from [2] but is 
computationally easier to implement, being based on the underlying system 
equations. After each iteration the current dosing scheme is updated based on 
a linear operator applied to the difference between achieved and desired target 
vectors. 
The iterative method is applied to the coupled PK-PD model from [1] in order to 
directly construct a dosing regime, rather than indirectly via a continuous 
efficacy profile. 
[1]  Mhawej MJ, Moog CH, Biafore F, Brunet-François C. Control of the HIV infection and drug dosage. 
Biomed Signal Process Control. 2010; 5: 45–52. doi:10.1016/j.bspc.2009.05.001 
[2]  Evans ND. Optimal oral drug dosing via application of the Contraction Mapping Theorem. Biomed 
Signal Process Control; in press. www.scipharm.at Scientia  Pharmaceutica  589 
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The pharmaceutical industry uses million of animals for in-vivo studies to 
discover or to develop novel pharmaceutics. Time and costs involved and the 
extrapolation to human physiology of the data obtained are the main difficulties 
of these studies. The alternative to laboratory animals is the development of in-
vitro  and  in-silico  models (which are physical and mathematical models 
respectively). 
In literature, different in-vitro models are proposed to reproduce the 
gastrointestinal tract taking in account both the mixing and the biochemical 
features. However, these models are not able to reproduce closely the real 
physiology. To describe the drug release in the human body, different kinds of 
mathematical models (in-silico  models) are proposed. Among these, 
physiologically-based pharmacokinetic models are more complex and complete: 
the body is divided into compartiments, corresponding to real structures of the 
body, each with a specific function. Despite their reliability, these models require 
the fitting of a lot of parameters. 
The aims of this work are to realize an in-vitro model reproducing the 
mechanical and biochemical features of the gastrointestinal tract and to 
develope (and validate) a novel physiologically-based model incorporating the 
pharmacokinetic and physiological parameters. 
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The proposed in-silico model is 
simple and is characterized by a 
limited number of parameters. 
Haematic drug levels after different 
kind of administrations have been 
successfully simulated. 
 
 
Fig. 1. Haematic drug concentration after the 
administration from three solid dosage forms 
(fast, medium and slow release). Symbols: 
experimental data, curves: model prediction. 
 